{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T23:32:05Z","timestamp":1784849525535,"version":"3.55.0"},"reference-count":39,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,18]],"date-time":"2023-08-18T00:00:00Z","timestamp":1692316800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100014942","name":"Novartis Gene Therapies","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014942","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1016\/j.ymthe.2023.08.013","type":"journal-article","created":{"date-parts":[[2023,8,18]],"date-time":"2023-08-18T21:33:29Z","timestamp":1692394409000},"page":"2991-2998","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"title":["Epithelioid neoplasm of the spinal cord in a child with spinal muscular atrophy treated with onasemnogene abeparvovec"],"prefix":"10.1016","volume":"31","author":[{"given":"Laura","family":"Retson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nishant","family":"Tiwari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Vaughn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saunder","family":"Bernes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P. David","family":"Adelson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith","family":"Mansfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvana","family":"Libertini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brent","family":"Kuzmiski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iulian","family":"Alecu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Gabriel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2288-042X","authenticated-orcid":false,"given":"Ross","family":"Mangum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymthe.2023.08.013_bib1","doi-asserted-by":"crossref","first-page":"6307","DOI":"10.1073\/pnas.96.11.6307","article-title":"A single nucleotide in the SMN gene regulates splicing and is responsible for spinal muscular atrophy","volume":"96","author":"Lorson","year":"1999","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2023.08.013_bib2","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1097\/00125817-200201000-00004","article-title":"Molecular analysis of spinal muscular atrophy and modification of the phenotype by SMN2","volume":"4","author":"Mailman","year":"2002","journal-title":"Genet. Med."},{"key":"10.1016\/j.ymthe.2023.08.013_bib3","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.nmd.2018.01.003","article-title":"Correlation between SMA type and SMN2 copy number revisited: An analysis of 625 unrelated Spanish patients and a compilation of 2834 reported cases","volume":"28","author":"Calucho","year":"2018","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.ymthe.2023.08.013_bib4","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1212\/WNL.0000000000000741","article-title":"Observational study of spinal muscular atrophy type I and implications for clinical trials","volume":"83","author":"Finkel","year":"2014","journal-title":"Neurology"},{"key":"10.1016\/j.ymthe.2023.08.013_bib5","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1002\/ana.25101","article-title":"Natural history of infantile-onset spinal muscular atrophy","volume":"82","author":"Kolb","year":"2017","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.ymthe.2023.08.013_bib6","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s13023-020-01356-1","article-title":"Longitudinal natural history of type I spinal muscular atrophy: a critical review","volume":"15","author":"Mercuri","year":"2020","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.ymthe.2023.08.013_bib7","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/j.nmd.2021.08.009","article-title":"Spinal muscular atrophy: from rags to riches","volume":"31","author":"Mercuri","year":"2021","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.ymthe.2023.08.013_bib8","series-title":"Spinraza [package Insert]","year":"2016"},{"key":"10.1016\/j.ymthe.2023.08.013_bib9","series-title":"Evrysdi [package Insert]","year":"2020"},{"key":"10.1016\/j.ymthe.2023.08.013_bib10","doi-asserted-by":"crossref","first-page":"7689","DOI":"10.1128\/JVI.77.13.7689-7695.2003","article-title":"Episomal persistence of recombinant adenoviral vector genomes during the cell cycle in\u00a0vivo","volume":"77","author":"Ehrhardt","year":"2003","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.ymthe.2023.08.013_bib11","series-title":"Zolgensma [package Insert]","year":"2021"},{"key":"10.1016\/j.ymthe.2023.08.013_bib12","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1706198","article-title":"Single-dose gene-replacement therapy for spinal muscular atrophy","volume":"377","author":"Mendell","year":"2017","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2023.08.013_bib13","doi-asserted-by":"crossref","first-page":"307","DOI":"10.3233\/JND-190403","article-title":"AVXS-101 (onasemnogene abeparvovec) for SMA1: comparative study with a prospective natural history cohort","volume":"6","author":"Al-Zaidy","year":"2019","journal-title":"J.\u00a0Neuromuscul. Dis."},{"key":"10.1016\/j.ymthe.2023.08.013_bib14","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/S1474-4422(21)00001-6","article-title":"Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy in patients with two copies of SMN2 (STR1VE): an open-label, single-arm, multicentre, phase 3 trial","volume":"20","author":"Day","year":"2021","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.ymthe.2023.08.013_bib15","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1016\/S1474-4422(21)00251-9","article-title":"Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy type 1 (STR1VE-EU): an open-label, single-arm, multicentre, phase 3 trial","volume":"20","author":"Mercuri","year":"2021","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.ymthe.2023.08.013_bib16","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1038\/s41591-022-01866-4","article-title":"Onasemnogene abeparvovec for presymptomatic infants with two copies of SMN2 at risk for spinal muscular atrophy type 1: the Phase III SPR1NT trial","volume":"28","author":"Strauss","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2023.08.013_bib17","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1038\/s41591-022-01867-3","article-title":"Onasemnogene abeparvovec for presymptomatic infants with three copies of SMN2 at risk for spinal muscular atrophy: the Phase III SPR1NT trial","volume":"28","author":"Strauss","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2023.08.013_bib18","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1177\/1060028020914274","article-title":"Onasemnogene abeparvovec-xioi: gene therapy for spinal muscular atrophy","volume":"54","author":"Stevens","year":"2020","journal-title":"Ann. Pharmacother."},{"key":"10.1016\/j.ymthe.2023.08.013_bib19","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1002\/ppul.24203","article-title":"Health outcomes in spinal muscular atrophy type 1 following AVXS-101 gene replacement therapy","volume":"54","author":"Al-Zaidy","year":"2019","journal-title":"Pediatr. Pulmonol."},{"key":"10.1016\/j.ymthe.2023.08.013_bib20","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.pediatrneurol.2019.05.005","article-title":"Impact of age and motor function in a phase 1\/2a study of infants with SMA type 1 receiving single-dose gene replacement therapy","volume":"98","author":"Lowes","year":"2019","journal-title":"Pediatr. Neurol."},{"key":"10.1016\/j.ymthe.2023.08.013_bib21","doi-asserted-by":"crossref","first-page":"163","DOI":"10.4103\/1658-631X.204857","article-title":"Spinal muscular atrophy and ependymoma","volume":"5","author":"Albakr","year":"2017","journal-title":"Saudi J. Med. Med. Sci."},{"key":"10.1016\/j.ymthe.2023.08.013_bib22","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1097\/00043426-200208000-00022","article-title":"Disseminated alveolar rhabdomyosarcoma in a child with spinal muscular atrophy","volume":"24","author":"Yaris","year":"2002","journal-title":"J.\u00a0Pediatr. Hematol. Oncol."},{"key":"10.1016\/j.ymthe.2023.08.013_bib23","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.nmd.2004.09.013","article-title":"Alveolar rhabdomyosarcoma in infantile spinal muscular atrophy: coincidence or predisposition?","volume":"15","author":"Rudnik-Sch\u00f6neborn","year":"2005","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.ymthe.2023.08.013_bib24","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1177\/0883073814542950","article-title":"Neuroblastoma in a patient with spinal muscular atrophy type I: is it just a coincidence?","volume":"30","author":"Sag","year":"2015","journal-title":"J.\u00a0Child Neurol."},{"key":"10.1016\/j.ymthe.2023.08.013_bib25","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1038\/ng1380","article-title":"Adeno-associated virus vectors integrate at chromosome breakage sites","volume":"36","author":"Miller","year":"2004","journal-title":"Nat. Genet."},{"key":"10.1016\/j.ymthe.2023.08.013_bib26","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1038\/mt.2016.17","article-title":"Genotoxicity in mice following AAV gene delivery: a safety concern for human gene therapy?","volume":"24","author":"Chandler","year":"2016","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2023.08.013_bib27","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1089\/hum.2017.009","article-title":"Recombinant adeno-associated viral integration and genotoxicity: insights from animal models","volume":"28","author":"Chandler","year":"2017","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2023.08.013_bib28","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1016\/j.ymthe.2021.03.009","article-title":"Liver gene therapy and hepatocellular carcinoma: a complex web","volume":"29","author":"de Jong","year":"2021","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2023.08.013_bib29","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1038\/mt.2016.52","article-title":"Recombinant AAV integration is not associated with hepatic genotoxicity in nonhuman primates and patients","volume":"24","author":"Gil-Farina","year":"2016","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2023.08.013_bib30","doi-asserted-by":"crossref","first-page":"2646","DOI":"10.1016\/j.ymthe.2022.06.004","article-title":"Evaluating the state of the science for adeno-associated virus integration: An integrated perspective","volume":"30","author":"Sabatino","year":"2022","journal-title":"Mol. Ther."},{"issue":"Suppl 2","key":"10.1016\/j.ymthe.2023.08.013_bib31","article-title":"Liver safety case report from the phase 3 HOPE-B Gene therapy trial in adults with hemophilia B [abstract]","volume":"5","author":"Schmidt","year":"2021","journal-title":"Res. Pract. Thromb. Haemost."},{"key":"10.1016\/j.ymthe.2023.08.013_bib32","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.omtm.2023.04.009","article-title":"Comparing molecular and computational approaches for detecting viral integration of AAV gene therapy constructs","volume":"29","author":"Oziolor","year":"2023","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.ymthe.2023.08.013_bib33","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1038\/s41467-017-01883-9","article-title":"DNA double-strand break repair pathway regulates PD-L1 expression in cancer cells","volume":"8","author":"Sato","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2023.08.013_bib34","doi-asserted-by":"crossref","first-page":"826608","DOI":"10.3389\/fncel.2022.826608","article-title":"R-loop mediated DNA damage and impaired DNA repair in spinal muscular atrophy","volume":"16","author":"Cuartas","year":"2022","journal-title":"Front. Cell. Neurosci."},{"key":"10.1016\/j.ymthe.2023.08.013_bib35","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1038\/nm.2057","article-title":"Comprehensive genomic access to vector integration in clinical gene therapy","volume":"15","author":"Gabriel","year":"2009","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2023.08.013_bib36","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1038\/nprot.2010.87","article-title":"Genome-wide high-throughput integrome analyses by nrLAM-PCR and next-generation sequencing","volume":"5","author":"Paruzynski","year":"2010","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.ymthe.2023.08.013_bib37","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1146\/annurev.genet.37.110801.143717","article-title":"Integration of adeno-associated virus (AAV) and recombinant AAV vectors","volume":"38","author":"McCarty","year":"2004","journal-title":"Annu. Rev. Genet."},{"key":"10.1016\/j.ymthe.2023.08.013_bib38","doi-asserted-by":"crossref","first-page":"8915","DOI":"10.1073\/pnas.91.19.8915","article-title":"Adeno-associated virus vectors preferentially transduce cells in S phase","volume":"91","author":"Russell","year":"1994","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2023.08.013_bib39","doi-asserted-by":"crossref","first-page":"2014","DOI":"10.1038\/mt.2012.220","article-title":"rAAV-mediated tumorigenesis: still unresolved after an AAV assault","volume":"20","author":"Valdmanis","year":"2012","journal-title":"Mol. Ther."}],"container-title":["Molecular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001623004458?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001623004458?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T18:10:07Z","timestamp":1761502207000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525001623004458"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":39,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["S1525001623004458"],"URL":"https:\/\/doi.org\/10.1016\/j.ymthe.2023.08.013","relation":{},"ISSN":["1525-0016"],"issn-type":[{"value":"1525-0016","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Epithelioid neoplasm of the spinal cord in a child with spinal muscular atrophy treated with onasemnogene abeparvovec","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymthe.2023.08.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s).","name":"copyright","label":"Copyright"}]}}